Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Other
    • Market Updates
    • Explainers
    • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
    • Posting Guidelines
  • Subscribe
Submit An Article

Latest Articles

  • SKS Technologies Moves to Expand NSW Footprint With Delta Elcom Acquisition
    SKS Technologies Moves to Expand NSW Footprint With Delta Elcom Acquisition
    • News

  • Monash University Partners with HITIQ to Advance Concussion Science Using Smart Mouthguards
    Monash University Partners with HITIQ to Advance Concussion Science Using Smart Mouthguards
    • News

  • Harris Technology targets return to profitability amid surging Refurbished Tech sales and Apple expansion
    Harris Technology targets return to profitability amid surging Refurbished Tech sales and Apple expansion
    • News

  • Pivotal Metals Secures $5.4M to Fast-Track Quebec Drill Program
    Pivotal Metals Secures $5.4M to Fast-Track Quebec Drill Program
    • News

  • Biotron Expands into Anaesthetics with Sedarex Acquisition and $2.5m Raise
    Biotron Expands into Anaesthetics with Sedarex Acquisition and $2.5m Raise
    • News

  • DroneShield Boosts Defence Capability with $13 Million Adelaide R&D Investment
    DroneShield Boosts Defence Capability with $13 Million Adelaide R&D Investment
    • News

  • Stakk Secures T-Mobile Contract to Power Super App Expansion
    Stakk Secures T-Mobile Contract to Power Super App Expansion
    • News

  • Medibank Backs Emyria with Landmark Depression Care Deal
    Medibank Backs Emyria with Landmark Depression Care Deal
    • News

  • NoviqTech Launches Quantum Intelligence Products, Opening Path to Enterprise-Grade Quantum AI
    NoviqTech Launches Quantum Intelligence Products, Opening Path to Enterprise-Grade Quantum AI
    • News

  • BRE Wins Final Permit to Advance Rare Earth Pilot Plant in Brazil
    BRE Wins Final Permit to Advance Rare Earth Pilot Plant in Brazil
    • News

The funs of chemistry: How this pharma company is tapping into lucrative waste management

  • In News
  • February 16, 2022
  • Samantha Freidin
The funs of chemistry: How this pharma company is tapping into lucrative waste management

Ever wondered how renewable fuel is made? Or how biodegradable plastics are created?

There’s a lot that happens after you throw something away, and the process of repurposing materials is more complex than you might think.

Clinical stage oncology company PharmAust (ASX: PAA) has an interesting subsidiary involved in just that. Epichem is a leading provider of synthetic and medicinal chemistry services. 

Epichem has recently successfully processed e-waste using a new technology as part of the $200,000 WasteSorted e-waste grant from the Western Australian Government New Industries Fund. 

The $16.7 million New Industries Fund is designed to boost new and emerging WA businesses to bolster the State’s economy and create job opportunities. 

The process of Oxidative Hydrothermal Dissolution (OHD) allows for the recovery of valuable metals and high value chemicals from e-waste. The benchtop device used the process of OHD to principally remove plastics, leaving concentrated major metals such as gold, tin, copper, iron and zinc. Minor metals such as silver, barium, nickel, chromium, magnesium and manganese were also recovered. 

Plastics removed were converted into small organic molecules that have the potential to be repurposed or even made biodegradable.

Adding to its appeal, the device is carbon neutral, environmentally sustainable using only oxygen and water at high temperatures and pressures to break down materials. 

The promising results have given Epichem renewed motivation to continue developing the OHD technology which is also capable of converting plastics into renewable fuels, or biodegradable products, turning rubber tyres into valuable chemical products and processing leftover stocks, crops and even trees into liquid fuel.

Epichem CEO, Colin La Galia said: “The e-waste project using OHD has delivered promising and encouraging results, We will continue to research and optimise the technology, process different waste streams and enter into commercial agreements with key stakeholders to validate their waste potential.”

This new venture raises questions about their ties to pharmaceutical company PharmAust but Epichem doesn’t just work in waste repurposing. The chemistry company primarily services the drug discovery and pharmaceutical industries by providing cost effective creation of drug analogues. Factor in their experience in chemistry and materials science and their new foray into waste management doesn’t seem so far fetched. 

The potential revenue streams from their OHD device are incredibly lucrative with the global waste management market expected to grow to $435 billion by 2023. This is only expected to grow as industries seek to reduce their environmental impact by repurposing their waste products into valuable end user products thereby reducing landfill and financial losses. 

  • About
  • Latest Posts
Samantha Freidin
Samantha Freidin is a business journalist at Emerald Financial whilst also completing a Masters of Marketing and Digital Communications at Monash University.
Latest posts by Samantha Freidin (see all)
  • Parkinson’s UK backs Pharmaxis with $5 million to slow the onset of incurable disease with ‘ground breaking’ trial - September 1, 2022
  • How this company is developing medtech to support Indigenous community health - August 22, 2022
  • A round of ap-paws for PharmAust, changing the ruff prognosis for dogs with lymphoma - August 17, 2022
  •  
  •  
  •  
  •  
  • asx paa
  • e-waste
  • epichem
  • paa
  • pharmaust
  • wastesorted
  • News

Leave a Comment

You must be logged in to post a comment.

  • About
  • Latest Posts
Samantha Freidin
Samantha Freidin is a business journalist at Emerald Financial whilst also completing a Masters of Marketing and Digital Communications at Monash University.
Latest posts by Samantha Freidin (see all)
  • Parkinson’s UK backs Pharmaxis with $5 million to slow the onset of incurable disease with ‘ground breaking’ trial - September 1, 2022
  • How this company is developing medtech to support Indigenous community health - August 22, 2022
  • A round of ap-paws for PharmAust, changing the ruff prognosis for dogs with lymphoma - August 17, 2022

Login or register for free to access unlimited reading

Register Now!
  • About
  • Latest Posts
Samantha Freidin
Samantha Freidin is a business journalist at Emerald Financial whilst also completing a Masters of Marketing and Digital Communications at Monash University.
Latest posts by Samantha Freidin (see all)
  • Parkinson’s UK backs Pharmaxis with $5 million to slow the onset of incurable disease with ‘ground breaking’ trial - September 1, 2022
  • How this company is developing medtech to support Indigenous community health - August 22, 2022
  • A round of ap-paws for PharmAust, changing the ruff prognosis for dogs with lymphoma - August 17, 2022
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.

Copyright © 2020 The Sentiment. All rights reserved.
Subscribe

Enter your email address below to subscribe to The Sentiment’s weekly newsletter, highlighting the top news, research, opinion and satire articles shaping ASX investor sentiment.

The Sentiment respects your privacy and will not spam you. View our privacy policy here.